Paclitaxel and its evolving role in the management of ovarian cancer

Nirmala @ Chandralega Kampan, Mutsa Tatenda Madondo, Orla M. McNally, Michael Quinn, Magdalena Plebanski

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.

Original languageEnglish
Article number413076
JournalBioMed Research International
Volume2015
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Taxoids
Paclitaxel
Platinum
Microtubules
Ovarian Neoplasms
Action Potentials
Primary Health Care
Appointments and Schedules
Safety
Cytotoxicity
Therapeutics
taxane

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Paclitaxel and its evolving role in the management of ovarian cancer. / Kampan, Nirmala @ Chandralega; Madondo, Mutsa Tatenda; McNally, Orla M.; Quinn, Michael; Plebanski, Magdalena.

In: BioMed Research International, Vol. 2015, 413076, 2015.

Research output: Contribution to journalArticle

Kampan, Nirmala @ Chandralega ; Madondo, Mutsa Tatenda ; McNally, Orla M. ; Quinn, Michael ; Plebanski, Magdalena. / Paclitaxel and its evolving role in the management of ovarian cancer. In: BioMed Research International. 2015 ; Vol. 2015.
@article{77fd73eafdff45d9aadc56cf1e40147d,
title = "Paclitaxel and its evolving role in the management of ovarian cancer",
abstract = "Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.",
author = "Kampan, {Nirmala @ Chandralega} and Madondo, {Mutsa Tatenda} and McNally, {Orla M.} and Michael Quinn and Magdalena Plebanski",
year = "2015",
doi = "10.1155/2015/413076",
language = "English",
volume = "2015",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Paclitaxel and its evolving role in the management of ovarian cancer

AU - Kampan, Nirmala @ Chandralega

AU - Madondo, Mutsa Tatenda

AU - McNally, Orla M.

AU - Quinn, Michael

AU - Plebanski, Magdalena

PY - 2015

Y1 - 2015

N2 - Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.

AB - Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.

UR - http://www.scopus.com/inward/record.url?scp=84934887048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934887048&partnerID=8YFLogxK

U2 - 10.1155/2015/413076

DO - 10.1155/2015/413076

M3 - Article

VL - 2015

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 413076

ER -